PDT Partners LLC purchased a new position in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 272,900 shares of the company’s stock, valued at approximately $22,460,000. Eli Lilly and comprises about 0.9% of PDT Partners LLC’s portfolio, making the stock its 27th largest position.
Other institutional investors have also recently made changes to their positions in the company. Acrospire Investment Management LLC grew its holdings in Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the last quarter. Point72 Asia Hong Kong Ltd grew its holdings in Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after acquiring an additional 1,239 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new stake in Eli Lilly and in the 2nd quarter worth $148,000. Cornerstone Advisors Inc. grew its holdings in Eli Lilly and by 18.4% in the 2nd quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock worth $166,000 after acquiring an additional 313 shares during the last quarter. Finally, American National Bank grew its holdings in Eli Lilly and by 5.2% in the 2nd quarter. American National Bank now owns 2,088 shares of the company’s stock worth $172,000 after acquiring an additional 104 shares during the last quarter. 75.48% of the stock is currently owned by institutional investors and hedge funds.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly and stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now directly owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The disclosure for this sale can be found here. Insiders sold 772,003 shares of company stock valued at $64,837,441 over the last ninety days. Corporate insiders own 0.20% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “PDT Partners LLC Invests $22.46 Million in Eli Lilly and Company (LLY) Stock” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://ledgergazette.com/2017/11/19/pdt-partners-llc-invests-22-46-million-in-eli-lilly-and-company-lly-stock.html.
A number of brokerages have issued reports on LLY. Morgan Stanley set a $86.00 price target on shares of Eli Lilly and and gave the stock a “hold” rating in a report on Friday, October 6th. Leerink Swann lifted their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, October 24th. Credit Suisse Group lowered shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their target price for the company from $84.23 to $88.00 in a research note on Tuesday, October 10th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $95.00 target price (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. Eli Lilly and presently has a consensus rating of “Hold” and a consensus target price of $89.76.
Eli Lilly and Company (LLY) opened at $82.89 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The stock has a market cap of $91,269.76, a PE ratio of 20.27, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $64.18 and a twelve month high of $89.09.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.88 earnings per share. sell-side analysts predict that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.51%. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.